O	0	11	Association
O	12	14	of
B-intervention	15	27	Transforming
I-intervention	28	34	Growth
I-intervention	35	41	Factor
I-intervention	42	43	Î²
I-intervention	44	56	Polymorphism
I-intervention	57	58	C
I-intervention	58	59	-
I-intervention	59	63	509T
O	64	68	With
B-condition	69	78	Radiation
I-condition	78	79	-
I-condition	79	86	Induced
I-condition	87	95	Fibrosis
O	96	101	Among
B-eligibility	102	110	Patients
I-eligibility	111	115	With
I-eligibility	116	121	Early
I-eligibility	121	122	-
I-eligibility	122	127	Stage
I-eligibility	128	134	Breast
I-eligibility	135	141	Cancer
O	141	142	:
O	143	144	A
O	145	154	Secondary
O	155	163	Analysis
O	164	166	of
O	167	168	a
O	169	179	Randomized
O	180	188	Clinical
O	189	194	Trial
O	194	195	.

O	196	203	Whether
O	204	211	genetic
O	212	219	factors
O	220	223	can
O	224	232	identify
O	233	241	patients
O	242	244	at
O	245	249	risk
O	250	253	for
O	254	263	radiation
O	263	264	-
O	264	271	induced
O	272	280	fibrosis
O	281	288	remains
O	289	300	unconfirmed
O	300	301	.

O	302	304	To
O	305	311	assess
O	312	315	the
O	316	327	association
O	328	335	between
O	336	339	the
O	340	341	C
O	341	342	-
O	342	346	509T
O	347	354	variant
O	355	361	allele
O	362	364	in
O	365	368	the
O	369	377	promoter
O	378	384	region
O	385	387	of
O	388	393	TGFB1
O	394	397	and
O	398	404	breast
O	405	413	fibrosis
O	414	415	3
O	416	421	years
O	422	427	after
O	428	440	radiotherapy
O	440	441	.

O	442	446	This
O	447	449	is
O	450	452	an
O	453	454	a
O	455	461	priori
O	461	462	-
O	462	471	specified
O	471	472	,
O	473	484	prospective
O	484	485	,
O	486	492	cohort
O	493	498	study
O	499	505	nested
O	506	508	in
O	509	511	an
O	512	516	open
O	516	517	-
O	517	522	label
O	522	523	,
O	524	534	randomized
O	535	543	clinical
O	544	549	trial
O	549	550	,
O	551	556	which
O	557	560	was
O	561	570	conducted
O	571	573	in
O	574	583	community
O	583	584	-
O	584	589	based
O	590	593	and
O	594	602	academic
O	603	609	cancer
O	610	617	centers
O	618	620	to
O	621	628	compare
O	629	645	hypofractionated
O	646	651	whole
O	651	652	-
O	652	658	breast
O	659	670	irradiation
O	671	672	(
O	672	675	WBI
O	675	676	)
O	677	678	(
O	678	680	42
O	680	681	.
O	681	683	56
O	684	686	Gy
O	687	689	in
O	690	692	16
O	693	702	fractions
O	702	703	)
O	704	708	with
B-control	709	723	conventionally
I-control	724	736	fractionated
I-control	737	740	WBI
O	741	742	(
O	742	744	50
O	745	747	Gy
O	748	750	in
O	751	753	25
O	754	763	fractions
O	763	764	)
O	765	770	after
O	771	777	breast
O	777	778	-
O	778	788	conserving
O	789	796	surgery
O	796	797	.

O	798	800	In
O	801	806	total
O	806	807	,
B-total-participants	808	811	287
O	812	817	women
B-age	818	820	40
I-age	821	826	years
I-age	827	829	or
I-age	830	835	older
B-eligibility	836	840	with
I-eligibility	841	855	pathologically
I-eligibility	856	865	confirmed
I-eligibility	866	871	stage
I-eligibility	872	873	0
I-eligibility	874	876	to
I-eligibility	877	880	IIA
I-eligibility	881	887	breast
I-eligibility	888	894	cancer
I-eligibility	895	902	treated
I-eligibility	903	907	with
I-eligibility	908	914	breast
I-eligibility	914	915	-
I-eligibility	915	925	conserving
I-eligibility	926	933	surgery
O	934	938	were
O	939	947	enrolled
O	948	952	from
O	953	961	February
O	962	966	2011
O	967	969	to
O	970	978	February
O	979	983	2014
O	983	984	.

O	985	993	Patients
O	994	998	were
O	999	1007	observed
O	1008	1011	for
O	1012	1013	a
O	1014	1021	minimum
O	1022	1024	of
O	1025	1026	3
O	1027	1032	years
O	1032	1033	.

O	1034	1042	Outcomes
O	1043	1047	were
O	1048	1056	compared
O	1057	1062	using
O	1063	1066	the
O	1067	1068	1
O	1068	1069	-
O	1069	1074	sided
O	1075	1081	Fisher
O	1082	1087	exact
O	1088	1092	test
O	1093	1096	and
O	1097	1110	multivariable
O	1111	1119	logistic
O	1120	1130	regression
O	1130	1131	.

O	1132	1133	A
O	1134	1135	C
O	1135	1136	-
O	1136	1138	to
O	1138	1139	-
O	1139	1140	T
O	1141	1147	single
O	1147	1148	-
O	1148	1158	nucleotide
O	1159	1171	polymorphism
O	1172	1174	at
O	1175	1183	position
O	1184	1185	-
O	1185	1188	509
O	1189	1197	relative
O	1198	1200	to
O	1201	1204	the
O	1205	1210	first
O	1211	1216	major
O	1217	1230	transcription
O	1231	1236	start
O	1237	1241	site
O	1242	1243	(
O	1243	1244	C
O	1244	1245	-
O	1245	1249	509T
O	1249	1250	)
O	1251	1253	of
O	1254	1257	the
O	1258	1263	TGFB1
O	1264	1268	gene
O	1268	1269	.

O	1270	1273	The
O	1274	1281	primary
O	1282	1289	outcome
O	1290	1293	was
B-outcome-Measure	1294	1299	grade
I-outcome-Measure	1300	1301	2
I-outcome-Measure	1302	1304	or
I-outcome-Measure	1305	1311	higher
I-outcome-Measure	1312	1318	breast
I-outcome-Measure	1319	1327	fibrosis
O	1328	1330	as
O	1331	1339	assessed
O	1340	1345	using
O	1346	1349	the
O	1350	1354	Late
O	1355	1362	Effects
O	1363	1369	Normal
O	1370	1376	Tissue
O	1376	1377	/
O	1377	1387	Subjective
O	1387	1388	,
O	1389	1398	Objective
O	1398	1399	,
O	1400	1407	Medical
O	1408	1418	Management
O	1418	1419	,
O	1420	1428	Analytic
O	1429	1434	scale
O	1435	1436	(
O	1436	1441	range
O	1441	1442	,
O	1443	1444	0
O	1445	1447	to
O	1448	1449	3
O	1449	1450	)
O	1451	1456	three
O	1457	1462	years
O	1463	1468	after
O	1469	1481	radiotherapy
O	1481	1482	.

O	1483	1488	Among
B-total-participants	1489	1492	287
O	1493	1498	women
O	1499	1507	enrolled
O	1508	1510	in
O	1511	1514	the
O	1515	1520	trial
O	1520	1521	,
O	1522	1527	TGFB1
O	1528	1536	genotype
O	1537	1540	and
O	1541	1542	3
O	1542	1543	-
O	1543	1547	year
O	1548	1560	radiotherapy
O	1560	1561	-
O	1561	1568	induced
O	1569	1577	toxicity
O	1578	1582	data
O	1583	1587	were
O	1588	1597	available
O	1598	1601	for
B-total-participants	1602	1605	174
O	1606	1614	patients
O	1614	1615	,
O	1616	1618	of
O	1619	1623	whom
O	1624	1626	89
O	1627	1635	patients
O	1636	1637	(
O	1637	1639	51
O	1639	1640	%
O	1640	1641	)
O	1642	1646	with
O	1647	1648	a
O	1649	1653	mean
O	1654	1655	(
O	1655	1657	SD
O	1657	1658	)
O	1659	1662	age
O	1663	1665	of
O	1666	1668	60
O	1669	1670	(
O	1670	1671	8
O	1671	1672	)
O	1673	1678	years
O	1679	1682	had
O	1683	1685	at
O	1686	1691	least
O	1692	1693	1
O	1694	1698	copy
O	1699	1701	of
O	1702	1703	C
O	1703	1704	-
O	1704	1708	509T
O	1708	1709	.

B-outcome	1710	1715	Grade
I-outcome	1716	1717	2
I-outcome	1718	1720	or
I-outcome	1721	1727	higher
I-outcome	1728	1734	breast
I-outcome	1735	1743	fibrosis
O	1744	1747	was
O	1748	1755	present
O	1756	1758	in
B-iv-bin-abs	1759	1761	12
O	1762	1764	of
B-intervention-participants	1765	1767	87
O	1768	1776	patients
O	1777	1781	with
O	1782	1783	C
O	1783	1784	-
O	1784	1788	509T
O	1789	1790	(
B-iv-bin-percent	1790	1792	13
I-iv-bin-percent	1792	1793	.
I-iv-bin-percent	1793	1794	8
I-iv-bin-percent	1794	1795	%
O	1795	1796	)
O	1797	1805	compared
O	1806	1810	with
B-cv-bin-abs	1811	1812	3
O	1813	1815	of
B-control-participants	1816	1818	80
O	1819	1827	patients
O	1828	1835	without
O	1836	1839	the
O	1840	1846	allele
O	1847	1854	variant
O	1855	1856	(
B-cv-bin-percent	1856	1857	3
I-cv-bin-percent	1857	1858	.
I-cv-bin-percent	1858	1859	8
I-cv-bin-percent	1859	1860	%
O	1860	1861	)
O	1862	1863	(
O	1863	1871	absolute
O	1872	1882	difference
O	1882	1883	,
O	1884	1886	10
O	1886	1887	.
O	1887	1888	0
O	1888	1889	%
O	1889	1890	;
O	1891	1893	95
O	1893	1894	%
O	1895	1897	CI
O	1897	1898	,
O	1899	1900	1
O	1900	1901	.
O	1901	1902	7
O	1902	1903	%
O	1903	1904	-
O	1904	1906	18
O	1906	1907	.
O	1907	1908	4
O	1908	1909	%
O	1909	1910	;
O	1911	1912	P
O	1913	1914	=
O	1915	1916	.
O	1916	1918	02
O	1918	1919	)
O	1919	1920	.

O	1921	1924	The
O	1925	1932	results
O	1933	1935	of
O	1936	1949	multivariable
O	1950	1958	analyses
O	1959	1968	indicated
O	1969	1973	that
O	1974	1978	only
O	1979	1980	C
O	1980	1981	-
O	1981	1985	509T
O	1986	1987	(
O	1987	1991	odds
O	1992	1997	ratio
O	1997	1998	,
O	1999	2000	4
O	2000	2001	.
O	2001	2003	47
O	2003	2004	;
O	2005	2007	95
O	2007	2008	%
O	2009	2011	CI
O	2011	2012	,
O	2013	2014	1
O	2014	2015	.
O	2015	2017	25
O	2017	2018	-
O	2018	2020	15
O	2020	2021	.
O	2021	2023	99
O	2023	2024	;
O	2025	2026	P
O	2027	2028	=
O	2029	2030	.
O	2030	2032	02
O	2032	2033	)
O	2034	2037	and
O	2038	2051	postoperative
O	2052	2060	cosmetic
O	2061	2068	outcome
O	2069	2070	(
O	2070	2074	odds
O	2075	2080	ratio
O	2080	2081	,
O	2082	2083	7
O	2083	2084	.
O	2084	2086	09
O	2086	2087	;
O	2088	2090	95
O	2090	2091	%
O	2092	2094	CI
O	2094	2095	,
O	2096	2097	2
O	2097	2098	.
O	2098	2100	41
O	2100	2101	-
O	2101	2103	20
O	2103	2104	.
O	2104	2106	90
O	2106	2107	;
O	2108	2109	P
O	2110	2111	<
O	2112	2113	.
O	2113	2116	001
O	2116	2117	)
O	2118	2122	were
O	2123	2136	significantly
O	2137	2147	associated
O	2148	2152	with
B-outcome	2153	2159	breast
I-outcome	2160	2168	fibrosis
I-outcome	2169	2173	risk
O	2173	2174	.

O	2175	2177	To
O	2178	2182	date
O	2182	2183	,
O	2184	2188	this
O	2189	2194	study
O	2195	2200	seems
O	2201	2203	to
O	2204	2206	be
O	2207	2210	the
O	2211	2216	first
O	2217	2228	prospective
O	2229	2239	validation
O	2240	2242	of
O	2243	2244	a
O	2245	2252	genomic
O	2253	2259	marker
O	2260	2263	for
O	2264	2273	radiation
O	2274	2282	fibrosis
O	2282	2283	.

O	2284	2287	The
O	2288	2289	C
O	2289	2290	-
O	2290	2294	509T
O	2295	2301	allele
O	2302	2304	in
O	2305	2310	TGFB1
O	2311	2313	is
O	2314	2315	a
O	2316	2319	key
O	2320	2331	determinant
O	2332	2334	of
O	2335	2341	breast
O	2342	2350	fibrosis
O	2351	2355	risk
O	2355	2356	.

O	2357	2366	Assessing
O	2367	2372	TGFB1
O	2373	2381	genotype
O	2382	2385	may
O	2386	2396	facilitate
O	2397	2398	a
O	2399	2403	more
O	2404	2416	personalized
O	2417	2425	approach
O	2426	2428	to
O	2429	2441	locoregional
O	2442	2451	treatment
O	2452	2461	decisions
O	2462	2464	in
O	2465	2471	breast
O	2472	2478	cancer
O	2478	2479	.

O	2480	2494	ClinicalTrials
O	2494	2495	.
O	2495	2498	gov
O	2499	2509	identifier
O	2509	2510	:
O	2511	2522	NCT01266642
O	2522	2523	.
